Profile data is unavailable for this security.
About the company
Cipla Limited is an India-based company, which is primarily engaged in the business of pharmaceuticals. The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The Company's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, the United States, South Africa, and Rest of the World. The Company has its network of manufacturing, trading and other incidental operations in India and International markets. The Company has approximately 47 manufacturing sites.
- Revenue in INR (TTM)253.50bn
- Net income in INR37.08bn
- Incorporated1935
- Employees26.62k
- LocationCipla LtdMumbai CentralMUMBAI 400013IndiaIND
- Phone+91 2 224826000
- Fax+91 2 224826120
- Websitehttps://www.cipla.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd | 126.34bn | 15.73bn | 563.83bn | 16.87k | 35.84 | -- | 30.17 | 4.46 | 131.58 | 131.58 | 1,056.65 | -- | -- | -- | -- | 7,488,804.00 | -- | 11.44 | -- | 17.01 | 59.75 | 58.84 | 12.46 | 13.31 | -- | 5.83 | -- | 30.96 | 9.08 | 12.52 | -40.19 | 9.30 | -19.38 | 13.97 |
| Aurobindo Pharma Ltd | 278.95bn | 27.70bn | 635.92bn | 15.69k | 22.97 | -- | 14.86 | 2.28 | 47.25 | 47.25 | 475.59 | -- | -- | -- | -- | 17,778,640.00 | -- | 9.84 | -- | 14.92 | 55.29 | 53.05 | 9.92 | 13.06 | -- | 23.89 | -- | 8.33 | 5.97 | 8.54 | -27.21 | -4.47 | 12.20 | 3.71 |
| Lupin Ltd | 194.80bn | 17.91bn | 733.25bn | 18.97k | 41.06 | -- | 26.06 | 3.76 | 39.19 | 39.19 | 426.18 | -- | -- | -- | -- | 10,268,360.00 | -- | 0.2337 | -- | 0.3443 | 64.99 | 58.56 | 9.29 | 0.3673 | -- | 6.89 | -- | 470.26 | 1.44 | 1.04 | 128.15 | 11.35 | -0.7025 | -4.36 |
| Torrent Pharmaceuticals Ltd | 104.74bn | 15.03bn | 852.83bn | 13.57k | 56.70 | -- | 37.09 | 8.14 | 44.44 | 44.44 | 309.68 | -- | -- | -- | -- | 7,716,901.00 | -- | 6.70 | -- | 10.48 | 74.12 | 70.84 | 14.35 | 11.22 | -- | 6.32 | -- | 63.62 | 13.07 | 10.09 | 60.22 | 12.92 | -6.22 | 25.74 |
| Mankind Pharma Ltd | 99.46bn | 17.27bn | 908.27bn | 18.47k | 52.63 | -- | 42.50 | 9.13 | 43.08 | 43.08 | 248.12 | -- | -- | -- | -- | 5,385,717.00 | -- | -- | -- | -- | 68.37 | -- | 17.68 | -- | -- | 144.35 | -- | -- | 12.44 | -- | -10.58 | -- | -- | -- |
| Zydus Lifesciences Ltd | 186.81bn | 29.56bn | 940.98bn | 23.03k | 32.02 | -- | 25.49 | 5.04 | 29.21 | 29.38 | 184.58 | -- | -- | -- | -- | 8,113,133.00 | -- | 7.92 | -- | 12.61 | 66.21 | 60.14 | 15.81 | 12.89 | -- | -- | -- | 20.55 | 14.08 | 7.59 | -12.34 | 1.83 | -0.3532 | 11.38 |
| Divi's Laboratories Ltd | 74.93bn | 13.83bn | 986.63bn | 16.95k | 71.32 | -- | 56.28 | 13.17 | 52.11 | 52.11 | 282.31 | -- | -- | -- | -- | 4,420,514.00 | -- | 18.50 | -- | 20.48 | 59.23 | 57.21 | 18.46 | 27.90 | -- | -- | -- | 31.31 | -13.31 | 14.70 | -38.41 | 15.76 | 11.55 | 24.57 |
| Dr Reddy's Laboratories Ltd | 272.13bn | 52.28bn | 1.00tn | 24.83k | 19.16 | -- | 15.06 | 3.68 | 313.75 | 313.75 | 1,633.13 | -- | -- | -- | -- | 10,958,640.00 | -- | 9.68 | -- | 13.81 | 70.55 | 65.53 | 19.21 | 12.76 | -- | 48.92 | -- | 17.84 | 14.50 | 11.55 | 106.94 | 33.23 | 11.31 | 14.87 |
| Cipla Ltd | 253.50bn | 37.08bn | 1.12tn | 26.62k | 30.09 | -- | 22.98 | 4.40 | 45.92 | 45.92 | 313.91 | -- | -- | -- | -- | 9,524,760.00 | -- | 8.61 | -- | 10.60 | 65.16 | 57.97 | 14.77 | 11.17 | -- | 47.26 | -- | 19.05 | 4.55 | 8.38 | 11.33 | 14.71 | 7.70 | 23.16 |
| Holder | Shares | % Held |
|---|---|---|
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 2024 | 36.00m | 4.46% |
| SBI Funds Management Ltd.as of 31 Mar 2024 | 34.12m | 4.23% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 27.96m | 3.46% |
| Norges Bank Investment Managementas of 30 Jun 2023 | 23.86m | 2.96% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 20.08m | 2.49% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 14.73m | 1.82% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Mar 2024 | 8.90m | 1.10% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 2024 | 7.77m | 0.96% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Mar 2024 | 7.68m | 0.95% |
| Geode Capital Management LLCas of 10 Apr 2024 | 6.19m | 0.77% |
